Obstructive Hypertrophic Cardiomyopathy

Assessing benefits of aficamten (Cytokinetics) on obstructive hypertrophic cardiomyopathy (HCM) symptom burden and QOL at 6 months.

NATIONAL HARBOR, Md. — Aficamten was associated with sustained improvement in patient-reported symptom burden and quality of life at 6 months when used to treat obstructive hypertrophic cardiomyopathy, a speaker reported.

Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently misunderstood, and often goes undiagnosed in clinical practice.

The American College of Cardiology Scientific Session was held April 2 to 4 in Washington, D.C. For the first time since 2019, the meeting was held inperson, and Healio Cardiology Today w onsite to cover the latest in cardiology.

Healio and Cardiology Today have compiled a list of the most-read news in cardiology of April 2022.

The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first cardiac myosin inhibitor to be permitted for use in the United States, Bristol Myers Squibb announced.

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy was associated with greater rate of 10-year all-cause death compared with septal myectomy, researchers reported.

Mavacamten (Bristol Myers Squibb) vs. placebo in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

WASHINGTON — The cardiac myosin inhibitor mavacamten, compared with placebo, reduced the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy, according to results of the VALOR-HCM trial.

Artificial intelligence to assess changes in ECGs may represent a novel method to evaluate disease status and treatment response to mavacamten in patients with obstructive hypertrophic cardiomyopathy, researchers reported.